SEC Form 4 · accession 0001225208-16-035824
Merck & Co., Inc. · MRK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Weir Mirian M Graddick
Officer — Exe V-P, HR
Period of report
Jul 1, 2016
Accepted (ET)
Jul 1, 2016 · 1:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000310158
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 1, 2016 | M | 30,000 | $40.70 | A | 162,151 | D | |
| Common StockF2,F3 | Jul 1, 2016 | S | 30,000 | $57.4851 | D | 132,151 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $40.70 | Jul 1, 2016 | M | 30,000 | D | Sep 1, 2007 | Aug 31, 2016 | Common Stock | 30,000 | 0 | D |
Explanation of responses
- F1The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.4300 to $57.6300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- F3Holdings include shares acquired in dividend reinvestment transactions.
- F4The option became exercisable in equal installments on 9/1/2007, 9/1/2008 and 9/1/2009.